targets, page-33

The reason for the company split and float in the US was to realise value pre HyAct results and assist with partnering. Give the trial will finish early next year (and I can't see another effort to float before that) then we don't need the split. Either we have a drug with efficacy or we don't. If we do, then everything will take care of itself. We will be able to choose from any number of partners. Given that, I don't see talk of splitting the company as realistic. I could be wrong, of course, but I just don't see the point.

-j